Research organisations join forces to develop treatments for neglected diseases

Mayor, Susan
June 2008
BMJ: British Medical Journal (International Edition);6/21/2008, Vol. 336 Issue 7658, p1396
Academic Journal
The author reports on a dual effort by the Institute of Research for Development and the Drugs for Neglected Diseases Initiative to develop medications to treat visceral leishmaniasis, Chagas's disease and sleeping sickness. According to the article, the research which is being done will focus on the development of different types of molecules which can potentially be used to treat the diseases. A description of the diseases being treated by the medications being developed through this partnership is given.


Related Articles

  • New Drugs for Neglected Diseases: From Pipeline to Patients. P├ęcoul, Bernard // PLoS Medicine;Oct2004, Vol. 1 Issue 1, p019 

    Focuses on the role of the Drugs for Neglected Diseases Initiative (DNDi) in the pharmaceutical industry. Discussion on funding for drug development; Mobilization for research and development resources of new drugs for neglected diseases; Information on the project portfolio of DNDi, including...

  • Major Four-year Project Launched to Treat Kala-Azar.  // India -- West;1/27/2012, Vol. 37 Issue 10, pA30 

    The article reports on the kala-azar, a comprehensive four-year project, launched by an international consortium for diagnosis and treatment of visceral leishmaniasis in India and Bangladesh.

  • Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study. Thakur, C.P.; Kumar, M.; Kumar, P.; Mishra, B.N.; Pandey, A.K. // British Medical Journal (Clinical Research Edition);6/4/1988, Vol. 296 Issue 6636, p1557 

    Evaluates the efficacy and safety of regimens for kala-azar with sodium stibogluconate treatment of patients in India. Number of patients with temperature returning to normal at the end of regimen treatment; Implication on the logistics regression of cured patients; Conclusion on sodium...

  • Evidence that the High Incidence of Treatment Failures in Indian Kala-Azar Is Due to the Emergence of Antimony-Resistant Strains of Leishmania donovani. Lira, Rosalia; Sundar, Shyam; Makharia, A.; Kenney, Richard; Gam, Albert; Saraiva, Elvira; Sacks, David // Journal of Infectious Diseases;8/1/99, Vol. 180 Issue 2 

    Investigates the treatment failures in Kala-Azar infection due to antimony-resistant strains of Leishmania donovani in India. Characterization of kala-azar; Use of splenic aspirates as a source material for the culture of promastigote; Susceptibility of intracellular amastigotes to sodium...

  • Correction: Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India. Ramesh, V.; Singh, Ruchi; Avishek, Kumar; Verma, Aditya; Deep, Deepak Kumar; Verma, Sandeep; Salotra, Poonam // PLoS Neglected Tropical Diseases;12/7/2015, Vol. 9 Issue 12, p1 

    A correction to the article "Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India," by V. Ramesh and colleagues is presented.

  • Gold treatment for kala-azar. Singh, M.P.; Mishra, M.; Khan, A.B.; Ramdas, S.L.; Panjiyar, S. // BMJ: British Medical Journal (International Edition);11/25/89, Vol. 299 Issue 6711, p1318 

    Investigates the use of gold treatment for patients with kala-azar. Enlargement of the liver; Occurrence of leishmania; Toxicity of the gold treatment.

  • Cost-Effectiveness Analysis of Combination Therapies for Visceral Leishmaniasis in the Indian Subcontinent. Meheus, Filip; Balasegaram, Manica; Olliaro, Piero; Sundar, Shyam; Rijal, Suman; Faiz, Md. Abul; Boelaert, Marleen // PLoS Neglected Tropical Diseases;Sep2010, Vol. 4 Issue 9, p1 

    Background: Visceral leishmaniasis is a systemic parasitic disease that is fatal unless treated. We assessed the cost and costeffectiveness of alternative strategies for the treatment of visceral leishmaniasis in the Indian subcontinent. In particular we examined whether combination therapies...

  • Montelukast is a useful adjunct in persistent asthma. Marcovitch, Harvey // BMJ: British Medical Journal (International Edition);3/8/2003, Vol. 326 Issue 7388, p521 

    Reports that montelukast is a useful adjunct in persistent asthma. Outline of two studies; Findings that the montelukast group had a more rapid response; Funding of the studies by pharmaceutical companies.

  • Comparison of regimens of treatment with sodium stibogluconate in kala-azar. Thakur, C.P.; Kumar, Mahendra; Singh, Satis Kumar; Sharma, Dilip; Prasad, Uma Shanker; Singh, Rama Shray Prasad; Dhawan, P.S.; Achari, Vijay // British Medical Journal (Clinical Research Edition);3/24/1984, Vol. 288 Issue 6421, p895 

    Investigates the regimen of treatment for kala-azar with sodium stibogluconate in Bihar, India. Treatment of 126 kala-azar infected patients; Similarity of symptomatic outcomes; Diagnosis of minor side effects.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics